Abstract
An α-Glucosidase inhibitor, acarbose, offers a novel approach in the treatment of diabetes mellitus. Although several symptoms of the digestive system are known to be side effects of acarbose, severe hepatic disease has also been reported. In this case, the alanine aminotransferase (ALT) level was observed to progressively increase after the administration of acarbose. There is little doubt that the patient suffered a drug-induced hepatic injury. In order to clarify the etiology of this increase in ALT, a drug-induced lymphocyte stimulation test and hepatitis virus marker test were performed and the administration of acarbose was discontinued. All laboratory tests showed negative results, and at 40 days after the administration, the ALT level was found to be near the normal range. A clinical pharmacist should monitor the parameters to assess the response and to document the absence of any side effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
